2026 – State Expert Center of the Ministry of Health of Ukraine

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product KONTROLFLEKS (tiocolchicoside). Important information on the risk of genotoxicity

02.10.2026 76

Information letter-notification for healthcare professionals on the potential risk of genotoxicity (aneuploidy) with the use of tiocolchicoside, in particular embryotoxic and teratogenic effects. Contains contraindications regarding pregnancy, breastfeeding and contraception, as well as recommendations on dosage and duration of treatment. compiled automatically

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

01.10.2026 63

Information letter-appeal for healthcare professionals on the safety of systemic fluoroquinolones: a reminder about restrictions on prescribing due to the risk of long-term serious adverse reactions and the procedure for reporting them. compiled automatically

Information letter-appeal to healthcare professionals regarding the medicinal product PARACETAMOL-BAXTER. Dosing tool, minimisation of the occurrence of a medication error leading to accidental overdose due to confusion between the units of measurement mg and ml

01.10.2026 78

Information letter-appeal for healthcare professionals regarding the safe use of a paracetamol-based medicinal product for infusion. Contains a dosing table depending on body weight and a dose calculation tool for the purpose of minimising the risk of accidental overdose due to confusion between mg and ml. compiled automatically

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Important information on minimising the risk of aortic aneurysm and dissection and cardiac valve regurgitation/insufficiency with the use of systemic and inhaled fluoroquinolones

30.09.2026 55

Information letter-appeal for healthcare professionals on the safety of systemic and inhaled fluoroquinolones: reminder of restrictions on use due to the risk of aortic aneurysm and dissection, cardiac valve regurgitation/insufficiency and other serious adverse reactions. Contains recommendations on prescribing, counselling patients and reporting adverse reactions. compiled automatically

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

29.09.2026 60

Information letter-appeal for healthcare professionals on the increased risk of mortality in intensive care unit patients under 65 years of age when using dexmedetomidine, based on the results of the SPICE III study. Contains a description of the evidence, risk factors and an update to the instructions for medical use. compiled automatically

Information letter addressed to healthcare professionals regarding the medicinal product Cabazitaxel Accord (cabazitaxel). Minimizing the potential risk of medication errors resulting from confusion of the concentration of the medicinal product.

21.09.2026 87

Information letter for healthcare professionals on the risk of medication errors due to confusion of concentrations of a medicinal product containing cabazitaxel. It contains recommendations on checking the product and correct dilution to avoid overdose or underdose. generated automatically

Patient card on the safe use of the medicinal product ENBREL® (etanercept)

11.09.2026 95

The patient card contains information on the safe use of the medicinal product Enbrel® (etanercept), in particular on the risk of infections, the need for tuberculosis screening, and reporting of adverse reactions. Intended for patients using this medicine and their doctors. generated automatically

Patient information cards on the safe use of the medicinal product Hyrimoz (adalimumab)

08.09.2026 112

Safety information cards for adult and pediatric patients treated with adalimumab, and for the physicians who prescribe it. They contain key information on possible adverse reactions, warnings about infections, tuberculosis, cancer, and vaccination, and recommendations for monitoring the patient's condition during treatment. compiled automatically

Informational letter addressed to healthcare professionals on CELLCEPT® (mycophenolate mofetil): Update on the period of contraception use after treatment completion for women of reproductive potential (extension from 6 weeks to 6 months)

01.09.2026 114

Information letter to healthcare professionals on updated contraception recommendations for women of reproductive potential who take mycophenolate mofetil: the period after the end of treatment has been extended from 6 weeks to 6 months. Contains information on teratogenic risks, contraindications and requirements for informing patients. generated automatically

Communication materials on the safe use of the medicinal product MITOXANTRONE “EBEWE

17.08.2026 173

Educational materials on the safe use of a medicinal product for the treatment of highly active relapsing multiple sclerosis. They contain instructions for physicians, a checklist, and information and a reminder card for patients on minimizing the risks of cardiotoxicity, genotoxicity, and hematotoxicity and on monitoring requirements. compiled automatically

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product KONTROLFLEKS (tiocolchicoside). Important information on the risk of genotoxicity

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

Information letter-appeal to healthcare professionals regarding the medicinal product PARACETAMOL-BAXTER. Dosing tool, minimisation of the occurrence of a medication error leading to accidental overdose due to confusion between the units of measurement mg and ml

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

Information letter addressed to healthcare professionals regarding the medicinal product Cabazitaxel Accord (cabazitaxel). Minimizing the potential risk of medication errors resulting from confusion of the concentration of the medicinal product.

Patient card on the safe use of the medicinal product ENBREL® (etanercept)

Patient information cards on the safe use of the medicinal product Hyrimoz (adalimumab)

Informational letter addressed to healthcare professionals on CELLCEPT® (mycophenolate mofetil): Update on the period of contraception use after treatment completion for women of reproductive potential (extension from 6 weeks to 6 months)

Communication materials on the safe use of the medicinal product MITOXANTRONE “EBEWE

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration